Kristen Kluska

“Congrats on this approval and appreciate you taking this program forward so that these patients now have an option. So I wanted to ask on patient identification efforts.”

“So sound, it's, you know, the things you mentioned today typically sound like the things that arise in the middle of a regulatory submission.”

“So sound, it's, you know, the things you mentioned today typically sound like the things that arise in the middle of a regulatory submission.”

“Hi, good afternoon, everybody, and congrats on all of the progress over this last quarter. While respecting your still very much in active review with the FDA, can you give us any high-level feedback on the mid-to-late cycle meeting?”